Keywords: Bristol-Myers Squibb, Brivanib, Liver cancer, Nexavar, Hepatocellular carcinoma

Bristol-Myers brivanib fails in Ph III liver cancer trial

Article | 20 July 2012

Print This

US drug major Bristol-Myers Squibb (NYSE: BMY) yesterday reported results of the Phase III BRISK-FL clinical trial of the investigational ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in